Funding Announcements
Week of March 8
DOD Prostate Cancer Grants
Pre-Application Deadline: May 5, 2010
More Information
The Fiscal Year (FY) Department of Defense 2010 Appropriation included $80 million for the Prostate Cancer Research Program (PCRP). The PCRP has released its final four program announcements for the following awards:
Laboratory-Clinical Transition Award
Supports goal- and product-driven preclinical studies of promising lead agents that have the potential to revolutionize prostate cancer clinical care. This award is intended to fund PIs who lack support to conduct the preclinical studies needed to advance lead agents to human testing. The goal of this award is the generation of pharmacology and toxicology data for inclusion in a U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) application prior to current Good Manufacturing Practice (cGMP) production of the lead agent(s). Agents supported by this award mechanism are expected to have high potential for commercial licensing for continued development and clinical use. Maximum funding is $750,000 for direct costs plus appropriate indirect costs, for a period of performance of up to three (3) years.
Physician Research Training Award
Supports a mentored training experience to prepare physicians with clinical duties and/or responsibilities for productive careers in prostate cancer research. Applications must include a robust description of an individualized training program appropriate to the area of study, which may include coursework and seminars, that will provide the Principal Investigator (PI) with experience in key areas such as statistics, bioethics, and/or relevant basic science disciplines. This award requires the involvement of a designated mentor with an established research program in prostate cancer. Maximum funding is $130,000 per year for direct costs plus appropriate indirect costs, for a minimum period of performance of three years and a maximum period of performance of five years.
Population-Based Research Award
Supports high-impact, population-based approaches to prostate cancer research. These studies, if successful, should contribute significantly to the elimination of death and suffering from prostate cancer. Proposed research must be responsive to at least one of the FY10 PCRP overarching challenges and at least one of the focus areas. The overall goal of this award is to generate unique information and/or tools that can only be achieved from the perspective of statistical analysis of a defined patient population. Maximum funding is $600,000 in direct costs plus appropriate indirect costs, for a period of performance of up to four (4) years.
Prostate Cancer Training Award
Supports postdoctoral training opportunities focused on prostate cancer research or patient care for individuals in the early stages of their careers. The trainee will be considered the Principal Investigator (PI) and author of the proposal. These awards primarily provide salary support for the PI and require the active involvement of a mentor who is an established prostate cancer researcher, as evidenced by a demonstrated record of funding and publications in prostate cancer research. The focus of these awards is on the PI, the mentor, and the training program and environment. Postdoctoral Ph.D. and M.D. PIs: The maximum period of performance is 2 years. The maximum allowable funding for the entire period of performance is $115,000 in direct costs.
Uniting Against Lung Cancer Research Grants
Deadline: May 14, 2010
More Information
Uniting Against Lung Cancer (formerly Joan’s Legacy) invites grant applications for institutional research that studies lung cancer. The Foundation is particularly interested in the genetic basis and biology of lung cancer, including that in never smokers, as well as novel therapeutic approaches for the treatment of this disease.
There will be two tracks of Lung Cancer Research Awards:
1. Adenocarcinoma, to include bronchioalveolar carcinoma (BAC)
2. Small cell lung cancer - new in 2009
Awards are generally made once a year. Each award is for $100,000 totalpaid in $50,000 disbursements over two years. This funding is intended primarily as seed money for promising new work. It is not for supporting research where funding has either lapsed or has been previously disapproved.
V Foundation Translational Grant
Deadline: June 4, 2010 5 PM EST
More Information
The V Foundation Translational Grant offers $600,000 paid in $200,000 installments over a three year period. Only two applicants per institution are permitted. If you'd like to be considered for this award, please contact Jill Penafiel at 303-724-3174 by April 20, 2010. You will need to submit your cover sheet (from the V Foundation website) a response of not more than 10 pages describing the specific aims, hypothesis, background, significance and proposed methods. For each person, submit a biosketch with other support. Submit a budget and a one page description of the project in lay terms.
Sontag Foundation Distinguished Scientist Awards
Deadline: March 24, 2010 at NOON ET
More Information
Sontag Foundation Accepting Applications for $600,000 Brain Tumor Research Awards Application deadline: Noon, Tuesday March 24, 2010
Applications are now being accepted for Distinguished Scientist Awards - The Sontag Foundation's four-year, $600,000 career development/brain tumor research grants. Eligible applicants must be within the first three years of their first independent faculty appointment at a tax-exempt 501(c)(3) academic, research, or medical institution within the United States or an equivalent institution in Canada. Proposed project must demonstrate potential to generate new knowledge relating to causes, cure or treatment of primary brain tumors/brain cancer.
The Sontag Foundation anticipates awarding three grants in 2010.
Full eligibility criteria and required forms are available at http://www.sontagfoundation.org/grant_opps/grant_opps_dsa.htm
BEFORE forwarding any questions, please consult FAQ at
http://www.sontagfoundation.org/grant_opps/grant_opps_dsa_faq.htm
Kay W. Verble, Executive Director
The Sontag Foundation
816 A1A North, Suite 201
Ponte Vedra Beach, FL 32082
904.273.8755
info@sontagfoundation.org
DOD Breast Cancer Funding Opportunities
Pre-Application Deadlines Vary: See individual Awards Below
More Information
The Fiscal Year 2010 (FY10) Defense Appropriations Act provides $150 million to the Department of Defense (DOD) Breast Cancer Research Program (BCRP) to promote innovative research focused on eradicating breast cancer.
Transformative Vision Award- Pre-proposal Deadline March 18, 2010
The BCRP Transformative Vision Award supports research projects to realize an extraordinary vision for dramatically affecting the prevention or treatment of breast cancer, and a plan to test and achieve the vision as quickly as possible. The maximum period of performance is 5 years. The maximum allowable funding for the entire period of performance is $12M in direct costs.
Multi-Team Award- Pre-proposal Deadline March 18, 2010
The BCRP Multi-Team Award supports the creation of a collaborative research project among three teams, each led by a Principal Investigator (PI) with a history of creativity and innovation, to focus on a critical area of breast cancer. The Multi-Team Award should create an environment that fosters and supports innovation and creativity, with consistent, intensive interaction across teams in a way that engages all members of the teams in all aspects of the research project. The maximum period of performance is 4 years. The maximum allowable funding for the entire period of performance is $4.5M in direct costs.
Era of Hope Scholar Award- Pre-application Deadline March 24, 2010
The Era of Hope Scholar Award supports individuals who are early in their careers and have high potential for innovation in breast cancer research. The maximum period of performance is 5 years. The maximum allowable funding for the entire period of performance is $2.5M in direct costs.
Innovator Award- Pre-application Deadline March 24, 2010
The Innovator Award supports visionary individuals who have demonstrated creativity, innovative work, and leadership in any field including, but not limited to, breast cancer. These individuals will have the most potential for future ground-breaking achievements in breast cancer.
The maximum period of performance is 5 years. The maximum allowable funding for the entire period of performance is $5M in direct costs.
Postdoctoral Fellowship Award- Pre-application Deadline March 24, 2010
The Postdoctoral Fellowship Award supports exceptionally talented recent medical or other doctoral graduates performing innovative, high-impact breast cancer research during their postdoctoral training, and allows them to obtain the necessary experience for an independent career at the forefront of breast cancer research. The maximum period of performance is 3 years. The maximum allowable funding for the entire period of performance is $300,000 in direct costs.
Idea Award- Pre-application Deadline April 21, 2010
The Idea Award is designed to promote new ideas that are still in the early stages of development and have the potential to yield highly impactful data and new avenues of investigation. This mechanism supports conceptually innovative, high-risk/high-reward research that could ultimately lead to critical discoveries or major advancements that will accelerate the eradication of breast cancer. The maximum period of performance is 2 years. The maximum allowable funding for the entire period of performance is $375,000 in direct costs.
Idea Award - Collaborative Option- Pre-application Deadline April 21, 2010
The Idea Award mechanism encourages applications that include meaningful and productive collaborations between two investigators. A separate award will be made to each PI’s institution. Maximum period of performance is 2 years. Maximum allowable, combined funding for the entire period of performance is $550,000 for direct costs.
Week of February 22
Webb-Waring Biomedical Research Awards
The Boettcher Foundation is proud to introduce the new Webb-Waring Biomedical Research Awards. This new grant program will ensure that the Webb-Waring legacy lives on both through the discovery of new knowledge that improves human health and through the investment in and advancement of young scientists.
The following information is of great importance to any individual submitting a Boettcher Webb-Waring grant proposal:
- The indirect cost (IDC) is 3.5% and must be included in the total budget requested. The total budget should not be less than $200K and not more than $350K. The funds can be payable over one, two or three years.
- You must provide three (3) letters of recommendation. One letter must come from your Department Chair, Division Head, Institute Head, Dean of your School, or some other academic authority. The second letter must come from a scientific content expert. The third letter must come from someone outside of the University of Colorado system. These letters of recommendation must be submitted separately to: richard.traystman@ucdenver.edu no later than March 26, 2010.
- Your budget must be reviewed by our Office of Grants and Contracts (OGC), and institutional certifications and assurances (IACUC, COMIRB) must be provided.
- Check your eligibility requirements: You must be within four (4) years of appointment to your first career-track academic position (date of appointment on or after November 1, 2005), and you must not have had a major, independent research award (R01 type). Recipients of K awards or R21 type (mentored) awards can be held simultaneously with the Boettcher Award (K99/R00are not eligible).
- The page limit of the proposal is 11 pages and this includes the reference list.
- The executive summary should be written for the lay reader and should include summary information about the investigator and the research proposed.
- Your grant proposal must be submitted to: webb-waring@cu.edu on or before March 15, 2010.
There will be a dual review process. UCDenver will review all applications received from UCDenver investigators and will select the highly recommended applicants in rank order (no more than one-third of the pool). All applications will be submitted to the Boettcher Webb-Waring review committee for final review of all University of Colorado system applications (UCDenver, Boulder and Colorado Springs ).
Two or three awards will be given this year to CU investigators. The announcement will be made on June 8, 2010 for funding beginning July 1, 2010.
European Respiratory Society
Deadline: March 8, 2010
More Information: www.ersnet.org/main-awards
The European Respiratory Society has several funding opportunities that are due very soon. Funding opportunities have strict rules, including membership to the ERS, age restrictions, etc. Please see the website for full details. Opportunites are directed at Lung, Head & Neck Cancers.
Week of Feburary 8
Cancer Research Institute Irvington Institute Fellowship Program
Deadline: April 1, 2010
More Information
The Irvington Institute Fellowship Program of the Cancer Research Institute, formerly the Cancer Research Institute Postdoctoral Fellowship Program, answers the need for more researchers in the field of cancer immunology. It supports qualified young scientists at leading universities and research centers around the world who wish to receive training in cancer immunology or general immunology.
The fellowship provides stipends of $45,000 for the first year, $47,000 for the second year and $49,000 for the third year. In addition, an allowance of $1,500 per year is allotted to the host institution for use at sponsor’s discretion to help pay for the fellow’s research supplies, travel to scientific meetings or health insurance. Stipends and institutional allowances are not permitted to cover administrative expenses. Payments are made monthly in U.S. currency to the host institution.
Week of February 1
DOD FY2010 Bone Marrow Failure Funding Opportunities
Deadlines vary: See individual awards below
More Information
The Department of Defense (DoD) Bone Marrow Failure Research Program (BMFRP) has released program announcements for Exploration-Hypothesis Development and New Investigator Awards. The objectives of the FY10 BMFRP are to fund scientifically meritorious research focused on BMF syndromes and their long-term sequelae. Studies that primarily focus on myeloproliferative neoplasms, leukemia, or other malignancies are discouraged. However, studies investigating BMF syndromes and their progression to other malignancies such as leukemia are acceptable. Proposals involving therapeutics, including but not limited to bone marrow transplantation, are strongly encouraged to address issues unique to BMF syndromes. The Fiscal Year (FY) DoD 2010 Appropriation included $3.75 million for the Bone Marrow Failure Research Program. The following funding mechanisms are offered:
Exploration-Hypothesis DevelopmentAwards (EHDA)- Pre-application deadline is March 25, 2010
This award is open to all investigators, supports initial exploration of innovative, untested, high-risk, potentially high-gain, and possibly groundbreaking concepts in bone marrow failure research. Results of studies conducted through this award may provide the scientific rationale upon which a new hypothesis can be based, or provide initial principals of an innovative hypothesis. The LOI narrative is limited to one page, the application project narrative is limited to three pages, the reviewers will be blinded as to the identity of the PI and the PI’s organization. Maximum funding $100,000 in direct costs plus indirect costs; period of performance cannot exceed 18 months.
New Investigator Awards (NIA)- Pre-application deadline is March 11, 2010
The intent of the BMFRP NIA is to support the career transition and/or continued development of promising, independent, non-mentored investigators, who are in the early stages of their scientific careers, in the field of BMF disease research. PI’s should have a strong desire to pursue a career as a BMF researcher and demonstrate the potential for a successful career focused on BMF research. Experience in BMF research is not required. PIs with a limited background in BMF research are strongly encouraged to include a collaborator who is experienced and has published in the field of BMF research. Additionally, the research proposed by the PI should include innovative ideas and approaches with the potential for high impact to meet the objectives of the FY10 BMFRP. Interesting features of this award include: new mechanism being offered for the first time in FY10, open to independent, non-mentored PIs at the level of Assistant Professor (or equivalent) with no more than six years at his/her current academic level at the time of the application submission deadline. Clinical trials are not allowed. Maximum funding of $400,000 in direct costs, period of performance cannot exceed three (3) years. Applicant may request the entire maximum direct cost amount for a project that may be less than the maximum 3-year period of performance.
DOD FY2010 Ovarian Cancer Funding Opportunities
Pre-Application Deadline: March 11, 2010
More Information
The Department of Defense (DoD) Ovarian Cancer Research Program (OCRP) has released program announcements for Pilot Awards and Translational Pilot Awards. The Fiscal Year (FY) DoD 2010 Appropriation included $18.75 million for the Ovarian Cancer Research Program.
Pilot Awards
The OCRP Pilot Award supports conceptually innovative, high-risk/high-reward research that could ultimately lead to critical discoveries or major advancements that will drive the field of ovarian cancer forward. Research priorities should include a testable hypothesis based on strong scientific rationale. Successful projects should provide a catalyst to expand or modify current thinking and/or approaches in ovarian cancer research. Preliminary data are not required, but are allowed. The strength of the proposal should be based on sound scientific rationale and logical reasoning. Clinical trials will not be supported by this award mechanism.
Translational Pilot Awards
This mechanism supports innovative translational research addressing a critical problem or question in ovarian cancer that will accelerate the movement of promising ideas toward clinical applications. The proposed research should provide a catalyst to challenge or expand current thinking and/or approaches to ovarian cancer. It must involve early-stage translation of an idea from the laboratory to the clinic, or from the clinic back to the laboratory. Observations that generate a translational pilot research idea may be derived from a laboratory discovery, literature review, population-based studies, novel findings from a clinical trial, or a clinician’s firsthand knowledge of patients and anecdotal data. Preliminary data are not required, but are allowed. The strength of the proposal should be based on sound scientific rationale and logical reasoning.
Wendy Will Case Cancer Fund, Inc. - Funding Opportunity
Deadline: April 1, 2010
More Information
Wendy Will Case died of cancer in November 1982, at the age of 39. In 1983, Wendy's family and friends established a fund to support promising researchers and help them establish "track records." To date, grants of over $2,500,000 have been made, mostly to researchers with innovative approaches. More than two-thirds have later received grants from NIH, NCI, ACS or other grantors.
The Case Fund Advisory Board is made of up some of the foremost authorities on cancer research in the United States . We invite you to submit your application keeping in mind the following information:
- We do not consider grants for the continuation of projects previously funded or to researchers with substantial outstanding grants.
- We are primarily interested in, but not limited to, clinically related research.
- We consider applications for one-year grants only, with budgets of $30,000 or les s.
- We will not fund the salary of the primary researcher. We will support assistants.
- We do not buy equipment - supplies only.
- We do not cover overhead costs such as rent, light, etc.
- Click here to obtain a Grant Application Summary. The Grant Application Summary form must be completed in all respects. Attach additional sheets as necessary. Also, please submit the same proposal as you did to major United States funders (NIH, NCI, ACS, etc.), after not receiving a grant from them, with a reworked budget to reflect our limitations. Include all such agency evaluations with your proposal. Generally, we do not consider applications which have not been reviewed by one or more of these major agencies.
- Closing dates for grant submissions are April 1 and October 1. Funding periods begin July 1 and January 1 of each year. Submit five copies of your proposal.
Fanconi Anemia Research Fund Research Grants
No Deadline
More Information
PLEASE NOTE: This announcement also contains RFAs for Head and Neck Carcinogenesis and Endocrine Organ Dysfunction. See website for additional details.
Our current research priorities are as follows:
- To identify the FA genes and their products and to understand their functions, interactions and roles in producing the clinical manifestations of Fanconi anemia.
- To advance basic and clinical research studies to improve FA diagnosis, therapy, and disease prevention.
- To determine the causes of bone marrow failure in Fanconi anemia, and to develop strategies to prevent, treat and cure bone marrow failure.
- To define the molecular pathogenesis of clonal evolution, carcinogenesis, and leukemogenesis in Fanconi anemia, and to develop strategies to prevent, treat and cure leukemia and other cancers.
- To support the creation of shared resources and technologies for the international Fanconi anemia research community
Principal investigators, post-doctoral fellows or grant coordinators may request a grant application packet. Grant proposals may be submitted at any time throughout the year.
Contact the Fund at info@fanconi.org or by telephone at 541-687-4658 or by fax at 541-687-0548 to request an application packet. The packet contains application forms and guidelines, conditions of award, and criteria for peer review.
Researchers should direct questions or concerns about the grant application process to Jeanne Negley, Executive Director. All project proposals are subject to rigorous peer review. Final funding decisions are made by the Fund's Board of Directors.
James S. McDonnell Foundation Collaborative Activity Awards
No Deadline
More Information
The Foundation offers Collaborative Activity Awards to initiate interdisciplinary discussions on problems or issues, to help launch interdisciplinary research networks, or to fund communities of researchers/practitioners dedicated to developing new methods, tools, and applications of basic research to applied problems. In each case the focus of the collaborative activity must meet the program guidelines for one of the following program areas:
- Bridging Brain, Mind, and Behavior
- Studying Complex Systems
- Brain Cancer Research
With the Collaborative Activity Awards, JSMF continues and formalizes a funding mechanism the Foundation has used since 1987. Over the past decade or so, the Foundation has from time to time provided grants to support study panels and research networks. This has proven to be an effective way to encourage cross-disciplinary thinking and research on fundamental questions. Furthermore, these activities have contributed to the development of programs both at the Foundation and at other funding agencies. Collaborative Activity Awards developed from questions or topics discussed at JSMF-sponsored meetings may be initiated by JSMF Advisory Panel members, particularly when the outcome of collaborative discussions assists with Foundation program planning.
NOTE: Collaborative awards will not be awarded in support of large, program-project style research proposals. Applicants requesting funds to support innovative research projects involving several laboratories should consider submitting one or more applications to the 21st Century Research Awards.
The budgets for collaborative activities will vary greatly depending on the scope of the proposed problem or project and on the number of people involved. The Foundation recognizes that funding must be appropriate to an activity's specific scope and needs. It also recognizes that organizing and implementing such an activity can be exceedingly time consuming.
Thus, rather than submit full proposals, applicants for Collaborative Activity Awards should submit a letter of inquiry. Letters of inquiry can be submitted at any time during the year, and must be submitted electronically to: collaborative @ jsmf.org. There are no application deadlines for these grants. Applicants can expect an initial response to their letters within 2-3 weeks of receipt.